Published in IBI on February 5, 2026, by Julie Ann Mayer, PhD
Ann, J., (2026) Optimising Clinical Trials Through Integrated Biomarker and Translational Data Models - Crown Bioscience. https://blog.crownbio.com/optimising-clinical-trials-through-integrated-biomarker-and-translational-data-models
Choosing the right preclinical immuno-oncology model makes or breaks your development decisions, but navigating the options is rarely simple. In this …
Read more
Immuno-oncology (IO) combination strategies depend on more than promising target biology. Translating a hypothesis about synergistic immune activation…
Read more
A review of Xie et al., "The molecular similarity landscape of preclinical cancer models to patient tumors," JCI Insight (2026) Model selection is one…
Read more